๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Metastatic Cancer
Clinical trial register · United States · industry-sponsored

Metastatic Cancer Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 19 Florida 14 Texas 9 Colorado 8 Missouri 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Mirati Therapeutics Inc.2 I-Mab Biopharma US Limited2 Sun Pharmaceutical Industries Limited1 Nectin Therapeutics Ltd1 Proviva Therapeutics, Inc.1
State
California19 Florida14 Texas9 Colorado8 Missouri7
All 33 states
Target enrolment
to
25 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
NCT07432295Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
I-Mab Biopharma US Limited
Phase 2
180
Arizona, California, Massachusetts
2026-02-11
Not yet open
CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer
NCT07057349Metastatic Cancer, Unresectable Solid Tumor
Cytosite Biopharma Inc.
Phase 1
40
Massachusetts
2025-09-01
Recruiting
SLV-154 Treatment of Advanced Cancers
NCT06771219Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
Solve Therapeutics
Phase 1
250
California, Missouri, New Jersey, New York, Ohio, Texas, Washington
2025-05-14
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia
2024-08-22
Recruiting
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
NCT06190886Advanced Cancer, Solid Tumor, Metastatic Cancer
Proviva Therapeutics, Inc.
Phase 1
26
California, Florida, Nebraska
2024-06-11
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
MacroGenics
Phase 1
250
California, Michigan, New York, Oregon, Texas, Utah
2024-03-06
Active, closed
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
Mirati Therapeutics Inc.
Phase 2
200
California, Missouri, North Carolina, Texas
2024-02-01
Recruiting
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
NCT06174987Advanced Cancer, Metastatic Cancer
Daiichi Sankyo
Phase 3
50
Florida, North Carolina
2024-01-05
Recruiting
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
NCT06090266Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer
OncoResponse, Inc.
Phase 1/2
168
Texas, Virginia
2023-10-24
Recruiting
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
NCT05877430NSCLC, HNSCC, Melanoma, Metastatic Cancer
CJ Bioscience, Inc.
Phase 1/2
160
California, Pennsylvania
2023-09-11
Active, closed
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
NCT05669482KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic
Verastem, Inc.
Phase 1/2
40
California, Illinois, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Utah
2023-03-22
Active, closed
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma
Jazz Pharmaceuticals
Phase 1
98
California, Colorado, Florida, Illinois, New York, Oklahoma, Pennsylvania, Tennessee
2022-10-10
Active, closed
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
NCT05378425Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
Nectin Therapeutics Ltd
Phase 1
90
California, Louisiana, Texas
2022-09-01
Recruiting
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
NCT05422911Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer
Sun Pharmaceutical Industries Limited
Phase 2
192
California, Florida, Michigan, Missouri, New York, North Carolina, Oregon, Pennsylvania
2022-08-31
Recruiting
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
NCT05394103Advanced Cancer, Metastatic Cancer
Qurient Co., Ltd.
Phase 1/2
130
Arizona, California, Florida, Illinois, Minnesota, New Jersey, Texas
2022-08-30
Recruiting
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
NCT05076760Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer
Memgen, Inc.
Phase 1
40
Florida, North Carolina
2022-04-21
Recruiting
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
Cogent Biosciences, Inc.
Phase 3
482
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Iowa
2022-04-14
Recruiting
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rฮฑ Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05267626Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Aulos Bioscience, Inc.
Phase 1/2
159
Florida, Michigan, Minnesota, Missouri, New Jersey, North Carolina, Tennessee, Texas
2022-04-04
Active, closed
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
NCT05103358Tumor, Tumor, Solid, Metastasis, Metastatic Cancer
Aadi Bioscience, Inc.
Phase 2
120
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2022-02-15
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
I-Mab Biopharma US Limited
Phase 1
330
California, Colorado, Indiana, Massachusetts, New Jersey, New York, North Carolina, Tennessee
2021-06-29
Recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Artios Pharma Ltd
Phase 1/2
542
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2021-01-27
Active, closed
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
NCT04648202Advanced Cancer, Metastatic Cancer
invoX Pharma Limited
Phase 1
82
Connecticut, Texas, Utah
2020-11-18
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
PMV Pharmaceuticals, Inc
Phase 1/2
300
California, Colorado, Connecticut, Delaware, Florida, Massachusetts, Michigan, Nebraska
2020-10-29
Active, closed
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Mirati Therapeutics Inc.
Phase 1/2
731
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2019-01-15
Active, closed
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
Eli Lilly and Company
Phase 2
309
Arizona, California, District of Columbia, Florida, Michigan, Missouri, Pennsylvania, Tennessee
2016-05-19
Rows per page Showing 1–25 of 25
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/metastatic-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.